PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer

Name: PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer
License: Public Domain

Institute of Cancer Research, United Kingdom

ClinicalTrials.gov · Datasets · License: Public Domain

Open Source ↗

breast neoplasm, triple negative breast cancer (tnbc), hrd

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 432895
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.